… ARPIs, including abiraterone acetate (Zytiga), … tolerability, comorbidities, drug–drug interactions, and … trials, reinforcing the external validity of trial … prostate cancer has entered an era of routine treatment intensification. Multiple ARPIs, chemotherapy …

… prostate cancer that has spread. The treatment is recommended for people where chemotherapy … eligible for the drug. Clinical trials found that … prostate cancer recommended by NICE in recent months, following darolutamide and abiraterone for prostate cancer …

… prostate cancer will have access to cheaper medicines on the Pharmaceutical Benefits Scheme (PBS). Abiraterone … ,200 patients accessed a comparable treatment through the PBS. Without subsidy …

… backbone of treatment for metastatic prostate cancer. However, … Agents such as abiraterone acetate (Zytiga), enzalutamide … advanced prostate cancer. Early involvement of medical oncology, … ARPIs, chemotherapy, targeted therapies, and clinical trial enrollment. …

… prostate cancer still represents an unmet medical … treatment for metastatic castrate-resistant prostate cancer (mCRPC). Eligible patients were chemotherapy … abiraterone treatment or were indicated for docetaxel treatment … is a pharmaceutical company specializing …

… treatment for men with untreated hormone-relapsed metastatic prostate cancer … standard treatment with abiraterone plus … trial, which included 805 men with castration-resistant prostate cancer … chemotherapy”.  Helen Knight, NICE's director of medicines …

… prostate cancer, traditional treatment methods such as androgen deprivation therapy and chemotherapy … responsiveness to chemotherapy drugs. The difference … et al. Abiraterone plus prednisone added … AE37-vaccinated prostate cancer patients reveal vaccine-specific …

… 42 million Transform trial, delivered in partnership with Prostate Cancer UK, which … potential to revolutionise prostate cancer screening and reduce unnecessary treatment. “The Secretary … NHS expanded access to abiraterone, a treatment that can significantly …

… Clinical trials have shown clear survival benefits for men with prostate cancer that … delivered. Abiraterone is now available as a lower‑cost generic medicine, … effective and evidence-based treatments, with several new prostate cancer drugs rolled over the …

… d'utilisation médicale secondaire assurera la … first-line treatment of metastatic castrate refractory prostate cancer: results … précédent traitement par abiratérone ou étaient indiqués … Science est une société pharmaceutique spécialisée dans la recherche …